---
title: "鐵貨折讓 16.39% 二供一  集資最多 3.26 億元"
description: "鐵貨公佈，建議進行二供一，發行 6.38 億股；供股價 0.51 元，較上交易日 (24 日) 收報折讓 16.39%。集資最多 3.26 億元，所得淨額 3.24 億元，擬用作償還應付 MIC 的借款本金；撥付 K&S 的採礦業務；及補充一般營運資金。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/262772977.md"
published_at: "2025-10-26T11:35:44.000Z"
---

# 鐵貨折讓 16.39% 二供一  集資最多 3.26 億元

> 鐵貨公佈，建議進行二供一，發行 6.38 億股；供股價 0.51 元，較上交易日 (24 日) 收報折讓 16.39%。集資最多 3.26 億元，所得淨額 3.24 億元，擬用作償還應付 MIC 的借款本金；撥付 K&S 的採礦業務；及補充一般營運資金。

鐵貨 (01029.HK) 公佈，建議進行二供一，發行 6.38 億股；供股價 0.51 元，較上交易日 (24 日) 收報折讓 16.39%。集資最多 3.26 億元，所得淨額 3.24 億元，擬用作償還應付 MIC 的借款本金；撥付 K&S 的採礦業務；及補充一般營運資金。

### Related Stocks

- [01029.HK - 鐵貨](https://longbridge.com/zh-HK/quote/01029.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| IRC Raises HK$326 Million via Rights Offering | IRC Raises HK$326 Million via Rights Offering | [Link](https://longbridge.com/zh-HK/news/275071479.md) |
| IRC Ltd. Announces Rights Issue Pending Fulfillment of Conditions | IRC Limited has announced a Rights Issue for existing shareholders to subscribe for additional shares, contingent on cer | [Link](https://longbridge.com/zh-HK/news/273290734.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-HK/news/276051793.md) |
| IRC Rights Issue Raises HK$323.6 Million and Lifts Axioma Capital’s Stake to Nearly 74% | IRC Limited has completed a rights issue, raising approximately HK$323.6 million, with Axioma Capital increasing its sta | [Link](https://longbridge.com/zh-HK/news/274981254.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-HK/news/276035104.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。